Table 5.
Treatment outcomes of all seven patients
| Case no. | Age/sex | Hematological malignancy | Chemotherapy | Response | SCT | Status | Overall survivala |
|---|---|---|---|---|---|---|---|
| 1 | 34/F | t-AML | FLAG | CR/MRD− | + | Alive | 19 mo |
| AZA + lirilumab | NR | ||||||
| Venetoclax + LDAC | NR | ||||||
| 2 | 32/F | t-MDS | Decitabine | CR/MRD+, followed by NR | + | Dead | 7 mo |
| 3 | 42/M | t-AML | CLIA | CR/MRD | + | Dead | 9 mo |
| SGN-CD33A | NR | ||||||
| Decitabine | NR | ||||||
| 4 | 28/F | t-AML | Decitabine + fludarabine + cytarabine + venetoclax | NR | − | Dead | 5 mo |
| 5 | 50/F | t-AML | Decitabine | NR | − | Alive | 12 mo |
| FLAG | CR/MRD− | ||||||
| Decitabine + venetoclax | CRi/MRD+ | ||||||
| 6 | 34/F | ALL | Obinutuzumab + hyper-CVAD | CR/MRD− | + | Alive | 23 mo |
| 7 | 24/M | Early precursor T-ALL | Hyper-CVAD + asparaginase + bortezomib | CR/MRD− | + | Dead | 23 mo |
| Nelarabine | NR | ||||||
| LY3039478 (investigational drug) | NR | ||||||
| C2V2E | NR | ||||||
| Decitabine + FIA | NR |
(SCT) Stem cell transplantation, (t-AML) therapy-related acute myeloid leukemia, (FLAG) fludarabine, cytarabine, and granulocyte colony-stimulating factor, (AZA) 5-azacitidine, (LDAC) low-dose ara-cytarabine, (CLIA) cladribine, idarubicin, and ara-cytarabine, (t-MDS) therapy-related myelodysplastic syndrome, (T-ALL) T-cell acute lymphoblastic leukemia, (C2V2E) clofarabine, cyclophosphamide, vincristine, velcade, etoposide, (FIA) fludarabine, idarubicin, and ara-cytarabine, (CVAD) cyclophosphamide, vincristine, doxorubicin (adriamycin), dexamethasone, (CR) complete remission, (NR) no response, (Cri) complete remission with incomplete count recovery, (MRD) minimal residual disease (assessed by multiparameter flow cytometry).
aSurvival from the diagnosis of hematological malignancy.